Iryna Pinchuk, Ph.D.
Assistant Professor, Division of Gastroenterology and Hetapology
Iryna Pinchuk, Ph.D.
Department of Internal Medicine
University of Texas Medical Branch
301 University Blvd.
Galveston, TX 77555-0655
Dr. Iryna Pinchuk is currently an Assistant Professor in the Division of Gastroenterology and Hepatology in the Department of Internal Medicine at The University of Texas Medical Branch (UTMB) in Galveston. She earned her PhD degree in Food and Biological Sciences from the University of Bordeaux I located in Talence, France. She then did postdoctoral fellowship at UT Health Center at Tyler, Texas and at UTMB at Galveston, Texas. Dr. Pinchuk's research during her postdoctoral fellowship at UTMB was supported by Crohn's & Colitis Foundation of America. She was promoted to Assistant Professor 2009. Her current research is supported by the American Gastroenterological Association (AGA Research Scholarship Award 2009-2011). Dr Pinchuk is co-author of a patent and has co-authored over 25 peer-reviewed journal articles and reviews.
Dr. Pinchuk's research interests are in the regulation of the human mucosal immune responses in acute and chronic inflammation, in particularly those involved in the progression of the inflammatory bowel disease (IBD) and colorectal cancer (CRC). A key event in an immune response is antigen recognition. Dr. Pinchuk has been characterizing a population of earlier non appreciated non professional antigen presenting cells (APCs), known as intestinal myofibroblasts/fibroblasts (IMFs or stromal cells) that are abundant in the human intestine and serve as a suppressor of acute inflammatory responses during mucosal tolerance. Currently, her studies are focused on the understanding of: (1) how different CD4+ T cell subtypes (in particularly, Th1, 2,17, 22 and CD4+ CD25high FoxP3+ regulatory T cells) are regulated by the IMFs when compare to professional APCs and epithelial cells; (2) how those T cell populations affect the phenotype and function of the stromal cells in gastro-intestinal tract; (3) how the stromal cells immusuppressive function is disrupted during acute and chronic inflammatory processes. Her research goal is to understand how the dysregulation of the interaction between those cells contribute to the disruption of the GI mucosal immune balance leading to the chronic inflammation that may results in the initiation of cancerogenesis during IBD and, finally, to CRC progression.
- Pinchuk IV, Saada JI, Beswick EJ, Boya G, Mittal S, DiMari J, Reyes VE and Powell, DW. Human colonic myofibroblasts promote the expansion of CD4+ CD25high FoxP3+ regulatory T cells. Gastroenterology. 2011. 2011 Mar 1. [Epub ahead of print].
- Mifflin RC, Pinchuk IV, Saada J, Powell DW. Intestinal Myofibroblasts: targets for stem cell therapy. Am J Physiol: Gastrointestinal Liver Physiol. 2011 Jan 20. [Epub ahead of print].
- Powell DW, Pinchuk IV, Saada JI, Chen X, Mifflin RC. Mesenchymal cells of the intestinal lamina propria. Annu. Rev. Physiol. 2011. 73:73:213-37.
- Pinchuk IV, Mifflin RC, Saada JI, Powell DW. Intestinal Mesenchymal cells. Current Gastroenterology Reports 12:310-8, 2010.
- Francoeur F, Bouatrouss Y, Seltana A, Pinchuk IV, Vachon PH, Powell DW, Sawan B, Seidman EG, Beaulieu JF. Degeneration of the pericryptal myofibroblast sheath by proinflammatory cytokine in inflammatory bowel diseases. Gastroenterology. 136: 268-277. 2009.
- Pinchuk IV, Saada JI, Beswick EJ, Boya G, Qiu SM, Mifflin RC, Raju GS, Reyes VE , Powell DW. PD-1 ligand expression by human colonic myofibroblasts/fibroblasts regulates CD4+ T cell activity. Gastroenterology.138:1228-1237. 2008.
- Pinchuk IV, Beswick EJ, Saada JI, Suarez G, Winston J, Mifflin RC, Di Mari JF, Powell DW, Reyes VE. MCP-1 production by intestinal myofibroblasts in response to Staphylococcal enterotoxin A: relevance to staphylococcal enterotoxigenic disease. J Immunol. 178:8097-8106, 2007.
- Beswick EJ, Pinchuk IV, Das S, Reyes VE. B7-H1 expression on gastric epithelial cells during Helicobacter pylori infection promotes the local development of CD25+ FoxP3+ T regulatory cells. Infect. Immun. 75:4334-4341, 2007.
- Saada JI, Pinchuk IV, Reyes VE, Barrera CA, Adegboyega PA, Suarez-Real G, Mifflin RC, DiMari JF, Powell DW. Subepithelial myofibroblasts are novel non-professional antigen presenting cells in the human colonic mucosa. J Immunol. 177:5986-5979, 2006.
The department of internal medicine is developing evidence based clinical protocols which will be available in EPIC (as order sets) for use when admitting patients with these diagnoses. Their AIM is to standardize care and decrease length of stay and readmission rates.Currently available protocols are:
- CAP - Community Acquired Pneumonia Order set
- Congestive Heart Failure (CHF)
- Chronic Obstructive Pulmonary Disease (COPD)
- Diabetic Ketoacidosis Adult, ICU
- General Medicine Admission
- Immunodeficiency Flow Panel
- MICU/CCU Admission Order Set
- Oral Analgesic Medications
- Parenteral Opioids
- Sepsis, Adult ICU
- 111 - Stroke Alert
- 112 - Stroke Activation
- 300086 - Stroke Floor Admission
- 3000000001 - Stroke Critical care without tPA
- 300088 Stroke - Transfer from Critical care to floor
- 3004002 - Stroke Discharge
All protocols can be found in the EPIC order set section.
The department of Internal Medicine has a large role in the Meaningful Use Initiative. Our participation is key for the success of the initiative. Please visit the meaningful use website for important communication and updates from the Meaningful Use Initiative.